142 related articles for article (PubMed ID: 23645236)
1. [Effects of ziprasidone and olanzapine on glucose and lipid metabolism in first-episode schizophrenia].
Shao P; Ou J; Wu R; Fang M; Chen H; Xu Y; Zhao J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 38(4):365-9. PubMed ID: 23645236
[TBL] [Abstract][Full Text] [Related]
2. Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia.
Ou JJ; Xu Y; Chen HH; Fan X; Gao K; Wang J; Guo XF; Wu RR; Zhao JP
Psychopharmacology (Berl); 2013 Feb; 225(3):627-35. PubMed ID: 22926006
[TBL] [Abstract][Full Text] [Related]
3. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
[TBL] [Abstract][Full Text] [Related]
4. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.
Breier A; Berg PH; Thakore JH; Naber D; Gattaz WF; Cavazzoni P; Walker DJ; Roychowdhury SM; Kane JM
Am J Psychiatry; 2005 Oct; 162(10):1879-87. PubMed ID: 16199834
[TBL] [Abstract][Full Text] [Related]
5. Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial.
Grootens KP; van Veelen NM; Peuskens J; Sabbe BG; Thys E; Buitelaar JK; Verkes RJ; Kahn RS
Schizophr Bull; 2011 Mar; 37(2):352-61. PubMed ID: 19542525
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine.
Brown RR; Estoup MW
Int Clin Psychopharmacol; 2005 Mar; 20(2):105-12. PubMed ID: 15729087
[TBL] [Abstract][Full Text] [Related]
7. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.
Wu RR; Zhao JP; Liu ZN; Zhai JG; Guo XF; Guo WB; Tang JS
Psychopharmacology (Berl); 2006 Jul; 186(4):572-8. PubMed ID: 16601995
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China.
Zhang Y; Dai G
Hum Psychopharmacol; 2012 Nov; 27(6):605-14. PubMed ID: 24446539
[TBL] [Abstract][Full Text] [Related]
9. Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.
Wu RR; Zhao JP; Zhai JG; Guo XF; Guo WB
J Clin Psychopharmacol; 2007 Aug; 27(4):374-9. PubMed ID: 17632222
[TBL] [Abstract][Full Text] [Related]
10. Effects of ziprasidone and olanzapine on body composition and metabolic parameters: an open-label comparative pilot study.
Park S; Yi KK; Kim MS; Hong JP
Behav Brain Funct; 2013 Jul; 9():27. PubMed ID: 23866300
[TBL] [Abstract][Full Text] [Related]
11. A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients.
Hu S; Yao M; Peterson BS; Xu D; Hu J; Tang J; Fan B; Liao Z; Yuan T; Li Y; Yue W; Wei N; Zhou W; Huang M; Xu Y
Psychopharmacology (Berl); 2013 Nov; 230(1):3-13. PubMed ID: 23559220
[TBL] [Abstract][Full Text] [Related]
12. Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial.
Lublin H; Haug HJ; Koponen H; Sigmundsson T; Kolb SA
World J Biol Psychiatry; 2009; 10(4 Pt 3):710-8. PubMed ID: 18803070
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controlled clinical trials.
Hoffmann VP; Case M; Stauffer VL; Jacobson JG; Conley RR
J Clin Psychopharmacol; 2010 Dec; 30(6):656-60. PubMed ID: 21105275
[TBL] [Abstract][Full Text] [Related]
14. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia.
Simpson GM; Weiden P; Pigott T; Murray S; Siu CO; Romano SJ
Am J Psychiatry; 2005 Aug; 162(8):1535-8. PubMed ID: 16055779
[TBL] [Abstract][Full Text] [Related]
15. Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia.
Henderson DC; Fan X; Copeland PM; Sharma B; Borba CP; Forstbauer SI; Miley K; Boxill R; Freudenreich O; Cather C; Evins AE; Goff DC
Hum Psychopharmacol; 2009 Apr; 24(3):225-32. PubMed ID: 19283774
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of ziprasidone vs. olanzapine in naive first-episode schizophrenia: a 6-week, randomized, open-label, flexible-dose study.
Li YM; Zhao JP; Ou JJ; Wu RR
Pharmacopsychiatry; 2012 Jul; 45(5):177-81. PubMed ID: 22290206
[TBL] [Abstract][Full Text] [Related]
17. A twenty-four-week, open-label study on ziprasidone's efficacy and influence on glucolipid metabolism in patients with schizophrenia and metabolic disorder.
Li CH; Shi L; Zhan GL; Rao SZ; Zhang H
Eur Rev Med Pharmacol Sci; 2013 Aug; 17(16):2136-40. PubMed ID: 23893178
[TBL] [Abstract][Full Text] [Related]
18. Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population.
Perez-Iglesias R; Mata I; Pelayo-Teran JM; Amado JA; Garcia-Unzueta MT; Berja A; Martinez-Garcia O; Vazquez-Barquero JL; Crespo-Facorro B
Schizophr Res; 2009 Feb; 107(2-3):115-21. PubMed ID: 18993033
[TBL] [Abstract][Full Text] [Related]
19. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms.
Kinon BJ; Lipkovich I; Edwards SB; Adams DH; Ascher-Svanum H; Siris SG
J Clin Psychopharmacol; 2006 Apr; 26(2):157-62. PubMed ID: 16633144
[TBL] [Abstract][Full Text] [Related]
20. Metabolic Effects of 7 Antipsychotics on Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial.
Zhang Y; Wang Q; Reynolds GP; Yue W; Deng W; Yan H; Tan L; Wang C; Yang G; Lu T; Wang L; Zhang F; Yang J; Li K; Lv L; Tan Q; Li Y; Yu H; Zhang H; Ma X; Yang F; Li L; Chen Q; Wei W; Zhao L; Wang H; Li X; Guo W; Hu X; Tian Y; Ren H; Ma X; Coid J; Zhang D; Li T;
J Clin Psychiatry; 2020 Mar; 81(3):. PubMed ID: 32237292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
